Eterna Therapeutics Financials
| ERNA Stock | USD 0.27 0.01 3.85% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.38 | 0.4021 |
|
| |||||
| Current Ratio | 1.34 | 0.8005 |
|
|
Investors should never underestimate Eterna Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Eterna Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Eterna Therapeutics.
Net Income |
|
Eterna | Select Account or Indicator |
Understanding current and past Eterna Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Eterna Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Eterna Therapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Eterna Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eterna Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Eterna Therapeutics' management manipulating its earnings.
Eterna Therapeutics Stock Summary
Eterna Therapeutics competes with Arcus Biosciences, Cullinan Oncology, Annexon, Structure Therapeutics, and Relay Therapeutics. Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Eterna Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 114082100 114082209 629410309 629410606 |
| Location | New York; U.S.A |
| Business Address | 1035 Cambridge Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | eternatx.com |
| Phone | 212 582 1199 |
| Currency | USD - US Dollar |
Eterna Therapeutics Key Financial Ratios
| Return On Equity | -11.54 | ||||
| Operating Margin | (7.87) % | ||||
| Price To Sales | 23.62 X | ||||
| Revenue | 582 K | ||||
| Gross Profit | 436 K |
Eterna Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 12.9M | 32.4M | 22.3M | 49.1M | 5.3M | 5.0M | |
| Other Current Liab | 966K | 1.1M | 4.0M | 882K | 1.0M | 1.9M | |
| Other Current Assets | 102K | 2.2M | 1.3M | 1.6M | 186K | 176.7K | |
| Total Liab | 5.2M | 25.9M | 10.2M | 46.9M | 3.6M | 3.4M | |
| Total Current Assets | 1.7M | 18.8M | 13.7M | 9.6M | 2.4M | 2.2M | |
| Net Debt | 1.3M | (14.3M) | (7.3M) | 34.3M | (1.0M) | (992.8K) | |
| Retained Earnings | (18.1M) | (159.7M) | (165.3M) | (187.0M) | (231.5M) | (220.0M) | |
| Accounts Payable | 1.3M | 1.8M | 1.6M | 1.1M | 1.7M | 1.8M | |
| Cash | 1.6M | 17.0M | 11.4M | 7.6M | 1.7M | 1.6M | |
| Net Receivables | 116K | 684K | 951K | 425K | 437K | 659.9K | |
| Short Term Debt | 799K | 852K | 2.0M | 4.4M | 207K | 196.7K | |
| Common Stock | 25.8M | 260K | 26K | 27K | 257K | 244.2K | |
| Other Liab | 930.4K | 23K | 48K | 1.6M | 1.9M | 2.0M | |
| Net Tangible Assets | 7.7M | 5.6M | 23.5M | 10.1M | 11.6M | 12.1M | |
| Other Assets | 7.3M | 6.4M | 1K | 5.2M | 4.7M | 4.2M |
Eterna Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Revenue | 19.8M | 5.8M | 0.0 | 68K | 582K | 552.9K | |
| Gross Profit | (98K) | (459K) | (497K) | (168K) | 486K | 461.7K | |
| Operating Income | (7.2M) | 68.3M | (33.2M) | (21.1M) | (15.7M) | (14.9M) | |
| Ebit | (7.2M) | (122.4M) | (33.7M) | (21.1M) | (17.3M) | (18.2M) | |
| Income Before Tax | (7.3M) | (122.3M) | (24.5M) | (21.7M) | (44.5M) | (42.3M) | |
| Net Income | 11.9M | (122.3M) | (24.6M) | (21.7M) | (44.6M) | (42.3M) | |
| Interest Expense | 43K | 74K | 30K | 614K | 6.8M | 7.1M | |
| Ebitda | (7.2M) | (121.9M) | (33.2M) | (19.9M) | (15.7M) | (14.9M) | |
| Cost Of Revenue | 98K | 459K | 497K | 236K | 96K | 91.2K | |
| Income Tax Expense | (19.2M) | 5K | 45K | (3K) | 30K | 31.5K | |
| Research Development | 4.0M | 12.7M | 10.4M | 5.9M | 4.6M | 6.9M |
Eterna Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (3.5M) | 15.4M | (1.4M) | (3.9M) | (9.9M) | (10.4M) | |
| Capital Expenditures | 39K | 154K | 297K | 19K | 369K | 526.9K | |
| End Period Cash Flow | 1.6M | 17.0M | 15.5M | 11.7M | 1.7M | 1.8M | |
| Free Cash Flow | (8.1M) | (23.6M) | (21.3M) | (20.4M) | (16.2M) | (17.0M) | |
| Depreciation | 98K | 459K | 497K | 1.1M | 1.6M | 1.6M | |
| Other Non Cash Items | 19.2M | 86.1M | (3.5M) | 1.0M | 27.5M | 34.5M | |
| Net Income | (7.3M) | (122.3M) | (24.6M) | (21.7M) | (44.5M) | (46.8M) | |
| Change To Netincome | 195.0K | 91K | 100.9M | (604K) | (694.6K) | (659.9K) |
Eterna Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eterna Therapeutics's current stock value. Our valuation model uses many indicators to compare Eterna Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eterna Therapeutics competition to find correlations between indicators driving Eterna Therapeutics's intrinsic value. More Info.Eterna Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Eterna Therapeutics' Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eterna Therapeutics' earnings, one of the primary drivers of an investment's value.Eterna Therapeutics Systematic Risk
Eterna Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eterna Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Eterna Therapeutics correlated with the market. If Beta is less than 0 Eterna Therapeutics generally moves in the opposite direction as compared to the market. If Eterna Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eterna Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eterna Therapeutics is generally in the same direction as the market. If Beta > 1 Eterna Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Eterna Therapeutics Financials
What exactly are Eterna Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Eterna Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Eterna Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Eterna Therapeutics investors may use each financial statement separately, they are all related. The changes in Eterna Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eterna Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Eterna Therapeutics Thematic Clasifications
Eterna Therapeutics is part of several thematic ideas from IT to Computers. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Eterna Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eterna Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Eterna Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Eterna Therapeutics March 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Eterna Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eterna Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eterna Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Eterna Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eterna Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 8.38 | |||
| Information Ratio | 0.0276 | |||
| Maximum Drawdown | 71.19 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 16.67 |
Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |